Computational studies of acetylcholinesterase complexed with fullerene derivatives: a new insight for Alzheimer disease treatment

J Biomol Struct Dyn. 2016 Jun;34(6):1307-16. doi: 10.1080/07391102.2015.1077345. Epub 2015 Oct 15.

Abstract

Here, we propose five fullerene (C60) derivatives as new drugs against Alzheimer's disease (AD). These compounds were designed to act as new human acetylcholinesterase (HssAChE) inhibitors by blocking its fasciculin II (FASII) binding site. Docking and molecular dynamic results show that our proposals bind to the HssAChE tunnel entrance, forming stable complex, and further binding free energy calculations suggest that three of the derivatives proposed here could be potent HssAChE inhibitors. We found a region formed by a set of residues (Tyr72, Asp74, Trp286, Gln291, Tyr341, and Pro344) which can be further exploited in the drug design of new inhibitors of HssAChE based on C60 derivatives. Results presented here report for the first time by a new class of molecules that can become effective drugs against AD.

Keywords: AChE inhibition; Alzheimer’s disease; docking; fullerene derivatives; molecular modeling; theoretical methodologies.

MeSH terms

  • Acetylcholinesterase / chemistry*
  • Acetylcholinesterase / metabolism
  • Binding Sites
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / metabolism
  • Cholinesterase Inhibitors / pharmacology
  • Drug Design
  • Fullerenes / chemistry*
  • Fullerenes / metabolism
  • Fullerenes / pharmacology
  • Models, Molecular*
  • Molecular Conformation*
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Protein Binding

Substances

  • Cholinesterase Inhibitors
  • Fullerenes
  • Acetylcholinesterase
  • fullerene C60